Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many statements about statin-associated skeletal muscle effects (myalgia, CK increase, rare rhabdomyolysis) and that risks increase with drug interactions are broadly consistent with the provided label excerpts. However, multiple claims introduce details not supported by the supplied prescribing information (e.g., “no well-established evidence” about exercise recovery slowing, specific likelihood statements by age/kidney/liver/hypothyroidism, and advice to prompt medical advice or to take a temporary break from training). Label excerpts also do not support several “more likely” or “often/should” style recommendations.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause muscle side effects in some people.
Supported by label section 5.1 (Atorvastatin occasionally causes myopathy; rare cases of rhabdomyolysis reported).
Statins like atorvastatin may be associated with muscle symptoms ranging from mild soreness to, rarely, serious muscle injury.
Partially supported by label 5.1 describing occasional myopathy and rare rhabdomyolysis; provided excerpts do not explicitly mention mild soreness as the spectrum.
Statin-related muscle effects can include muscle aches or soreness (myalgia).
Supported by label 6.1 listing myalgia among adverse reactions leading to discontinuation and as commonly reported adverse reaction content (myalgia is included as a clinical trial discontinuation adverse experience).
Statin-related muscle effects can include higher creatine kinase (CK) levels.
Not explicitly supported in the provided excerpts; however myopathy/rhabdomyolysis are discussed (CK testing not stated in provided text).
Statin-related muscle effects can rarely include severe muscle breakdown (myopathy/rhabdomyolysis).
Supported by label 5.1: rare cases of rhabdomyolysis with acute renal failure reported; atorvastatin occasionally causes myopathy.
Clinicians may hold the statin and evaluate for statin-associated muscle injury, particularly if CK is elevated.
Supported generally by label 5.1: therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy. CK-specific criterion is not in provided excerpts.
Risk of statin muscle symptoms can be higher with drug interactions that increase atorvastatin levels in the blood.
Supported by label 5.1 and 7: concomitant use with cyclosporine or strong CYP3A4 inhibitors increases risk of myopathy/rhabdomyolysis; 7.2 grapefruit juice can increase atorvastatin plasma concentrations.
Risk can be higher with medical conditions that raise statin levels in the blood.
Not supported in the provided excerpts (label text provided does not identify specific medical conditions that raise atorvastatin levels).
Unsupported Statements
There is no well-established evidence that Lipitor reliably slows muscle healing after normal exercise in most patients.
Not supported by any provided label excerpts (no discussion of exercise recovery or evidence statements).
Exercise recovery may feel unaffected for many people on statins.
Not supported by the provided label excerpts.
Statin-related muscle effects can include muscle weakness.
Not explicitly supported by the provided excerpts.
Statin-related muscle effects can include muscle cramps.
Not explicitly supported by the provided excerpts.
Clinicians may check creatine kinase (CK) to assess muscle injury when considering statin-associated muscle effects.
CK testing is not mentioned in the provided excerpts.
Risk can be higher with medical conditions that raise statin levels in the blood.
Specific medical conditions raising atorvastatin levels are not described in the provided excerpts.
Muscle symptoms are more likely with higher statin doses.
Provided excerpts do not state dose–likelihood relationship for muscle symptoms.
Muscle symptoms are more likely in older age.
Not supported by provided excerpts.
Muscle symptoms are more likely with kidney or liver disease.
Provided excerpts mention acute renal failure as a complication of rhabdomyolysis but do not state increased likelihood with kidney disease; liver dysfunction section excerpt is about transaminases and contraindication, not muscle-symptom likelihood.
Muscle symptoms are more likely with untreated hypothyroidism.
Not supported by provided excerpts.
Muscle symptoms are more likely with significant drug interactions that increase atorvastatin levels.
Drug-interaction increased risk is supported, but the “more likely” phrasing and emphasis on “increase atorvastatin levels” for all significant interactions is not explicitly detailed beyond provided examples.
Muscle symptoms are more likely with heavy or unaccustomed strenuous exercise.
Not supported by the provided excerpts.
If a person notices consistent muscle symptoms after workouts, they may need a temporary break from training until symptoms settle.
Not supported by provided label excerpts (no patient training/exercise instruction).
If a person notices consistent muscle symptoms after workouts, clinicians may check the statin dose and possible drug interactions.
Checking dose and evaluating drug interactions is not explicitly described in provided excerpts (label provides withholding/discontinuation in serious suggestive myopathy and highlights certain interactions).
If a person notices consistent muscle symptoms after workouts, clinicians may perform lab testing, often creatine kinase (CK).
CK lab testing is not mentioned in the provided excerpts.
If a person notices consistent muscle symptoms after workouts, a medication adjustment or switch may be considered if symptoms are judged statin-related.
Provided excerpts state temporarily withheld or discontinued in serious suggestive myopathy, but do not mention switching/adjustment wording.
Statin-related muscle effects can include higher creatine kinase (CK) levels.
CK is not mentioned in the provided excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warnings, contraindications (pregnancy/lactation, active liver disease) and their explicit wording were not addressed by the AI claims shown.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
The response includes several patient-management and risk-likelihood statements not supported by the provided label excerpts (e.g., CK testing, dose/age/kidney/liver/hypothyroidism/exercise likelihood, and advice to take a training break). While it generally reflects skeletal muscle risks and interaction-related increased risk, unsupported guidance could mislead clinical decision-making or patient expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts, including CK testing, exercise-recovery assertions, and specific likelihood modifiers (age, kidney/liver disease, hypothyroidism, strenuous exercise) and patient action steps (training break).
Suggested Improvement
Limit muscle-symptom statements to what is supported: that atorvastatin occasionally causes myopathy and rarely rhabdomyolysis, that certain drug interactions (cytosporine/strong CYP3A4 inhibitors) increase risk, and that therapy should be temporarily withheld or discontinued for an acute, serious condition suggestive of myopathy. Remove unsupported claims about CK testing, likelihood by specific patient factors, and exercise/workout guidance.